SEP 29, 2015 03:37 PM PDT

Switching On Immune Cells for Cancer Therapy

Killer T cells (green and red) surrounding a cancer cell.UC San Francisco scientists have developed a molecular “on switch” enabling tight control over the actions of T cells, immune system cells that have potential as cancer therapies. The innovation could sharply reduce severe, sometimes fatal side effects that have been a problem in advancing T cell-based treatments.

According to Wendell Lim, Ph.D., professor and chair of UCSF’s Department of Cellular and Molecular Pharmacology, and senior author of a new paper on the work, “Right now we put engineered T cells into patients and just hope for the best. This is the first of a series of ‘control knobs’ our lab is trying to create so doctors might have additional command over these cells once they’re inside the body.”

Scientists pursuing cell therapy have been refining cell-surface sensors called chimeric antigen receptors, or CARs. The CARs prompt T cells to zero in on particular proteins found primarily in tumors, where they launch cancer-killing immune responses.

CAR-equipped T cells can be successful in the treatment of chemotherapy-resistant leukemia, but they can cause side effects so severe that they may require monitoring in an Intensive Care Unit. Some patients have died after receiving CAR T cells or other engineered T cells.

Lim explained, “T cells are really powerful beasts, and they can be lethal when they’re activated. We’ve needed a remote control system that retains the power of these engineered T cells, but allows us to communicate specifically with them and manage them while they’re in the body.”

While some scientists have developed “suicide switches” that kill off CAR T cells if side effects become too dangerous, Lim thinks “that’s like shooting your own soldiers in the back. It requires completely aborting a complex and expensive treatment.”

As published in the September 24 issue of Science Express and reported in Bioscience Technology, the UCSF team took the opposite approach, creating a new type of CAR T cell that is “off” by default. In the same way as conventional CAR T cells, according to the article, “These newly developed T cells will navigate toward and interact with cancer cells, but will not launch any immune assault unless a specially designed drug has been administered. This controller drug forms a chemical bridge between components inside the CAR T cells, flipping the cells into an active, on status. When the drug is no longer present, the T cells revert to an off position.”
 
Lim concluded, “That we can engineer CAR T cells to have slightly different, quite powerful effects – even if for a subset of patients or for certain types of cancer – is really remarkable, and this is just the tip of the iceberg.”


 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAY 30, 2018
Cannabis Sciences
MAY 30, 2018
Cannabinoid Receptor Role in Inhibition of Renal Cell Carcinoma
Researchers investigated the potential connections between the endocannabinoid system and tumor cell growth inhibition in renal cell carcinoma....
JUN 05, 2018
Cancer
JUN 05, 2018
Early Breast Cancer Patients Do Not Gain Response Advantage with Chemotherapy
Phase III clinical trial research shows evidence that early breast cancer patients with common breast cancer type do not need chemotherapy & hormone therapy combo; hormone therapy is enough...
AUG 07, 2018
Cancer
AUG 07, 2018
Is There a Best Time of Day to Administer Chemo?
A common hematologic cancer chemotherapy agent is looked at for its efficacy on solid tumors and specifically evaluates if delivery time during the day affects is anti-tumor activity....
AUG 08, 2018
Immunology
AUG 08, 2018
Doxorubicin Causes Heart Toxicity by Immune System Disruption
Chemotherapy drug Doxorubicin disrupts metabolism that controls immune responses in the heart leading to heart toxicity....
AUG 13, 2018
Videos
AUG 13, 2018
What does sunscreen look like with a UV camera?
  Have you ever wondered if there’s really a difference between SPF 30 and SPF 50? You’re not the only one. YouTuber Physics Girl set out...
SEP 12, 2018
Microbiology
SEP 12, 2018
Researchers ID a Link Between a Bacterial Strain and Gastric Cancer
Helicobacter pylori is a bacterium that causes stomach ulcers, and can lead to gastric cancer....
Loading Comments...